


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 TRANSMITTAL FORM <small>(to be used for correspondence after initial filing)</small>		Application Number	09/709,045
		Filing Date	November 10, 2000
		First Named Inventor	M. Rigdon Lentz
		Art Unit	1647
		Examiner Name	Lorraine Spector
Total Number of Pages in This Submission		Attorney Docket Number	LEN 102


ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 15 pages of PTO-1449; 194 references; return postcard
<input type="text"/> Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Pabst Patent Group LLP		
Signature			
Printed name	Tiffany B. Salmon		
Date	April 29, 2005	Reg. No.	55,589

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Ronna Berman	Date	April 29, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Receipt date: 05/04/2005

09709045 GAU: 1647
PROSPECTIVE (12-04)

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

<p>Effective on 12/08/2004. Fee pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).</p> <p>FEE TRANSMITTAL For FY 2005</p> <p><input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27</p> <p><input checked="" type="checkbox"/> TRADE</p> <p>TOTAL AMOUNT OF PAYMENT (\$ 180.00)</p>		Complete if Known <table border="1"> <tr> <td>Application Number</td> <td>09/709,045</td> </tr> <tr> <td>Filing Date</td> <td>November 10, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>M. Rigdon Lentz</td> </tr> <tr> <td>Examiner Name</td> <td>L. Spector</td> </tr> <tr> <td>Art Unit</td> <td>1647</td> </tr> <tr> <td>Attorney Docket No.</td> <td>LEN 102</td> </tr> </table>		Application Number	09/709,045	Filing Date	November 10, 2000	First Named Inventor	M. Rigdon Lentz	Examiner Name	L. Spector	Art Unit	1647	Attorney Docket No.	LEN 102
Application Number	09/709,045														
Filing Date	November 10, 2000														
First Named Inventor	M. Rigdon Lentz														
Examiner Name	L. Spector														
Art Unit	1647														
Attorney Docket No.	LEN 102														

METHOD OF PAYMENT (check all that apply)

<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	<input type="checkbox"/> Money Order	<input type="checkbox"/> None	<input type="checkbox"/> Other (please identify): _____
<input checked="" type="checkbox"/> Deposit Account		Deposit Account Number: 50-3129		Deposit Account Name: Pabst Patent Group LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent

Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent

Multiple dependent claims

Total Claims	Extra Claims		Fee Paid (\$)	Multiple Dependent Claims		Small Entity
	Fee (\$)	Fee (\$)		Fee (\$)	Fee (\$)	
14 - 20 or HP =	0	x 0.00	= 0.00			50 25
HP = highest number of total claims paid for, if greater than 20						
Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)			200 100
2 - 3 or HP =	0	x 0.00	= 0.00			360 180
HP = highest number of independent claims paid for, if greater than 3						

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(e).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number) x	=	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Information Disclosure Statement

180.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	55,589	Telephone	(404) 879-2153
Name (Print/Type)	Tiffany B. Salmon			Date	April 29, 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Rigdon Lentz

Serial No.: 09/709,045

Art Unit: 1647

Filed: November 10, 2000

Examiner: Lorraine Spector

For: *METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, Applicants submit a Supplemental Information Disclosure Statement, including fifteen (15) pages of Form PTO-1449, and copies of the one hundred and ninety-four (194) documents cited therein.

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. § 1.98. Applicants respectfully request consideration of this Information Disclosure Statement. The Commissioner is authorized to charge \$180.00, the fee set forth under 37 CFR § 1.17(p), to Account No. 50-3129, if necessary. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

05/03/2005 HDESTA1 00000080 503129 09709045
01 FC:1806 180.00 DA

45056504V1

U.S.S.N.: 09/709,045

Filed: November 10, 2000

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

References duplicative of those cited on
the IDS form itself. /CMW/

U.S. Patent Applications

<u>Number</u>	<u>Publication Date</u>	<u>Inventor</u>	<u>Class/Subclass</u>
2001/0010818	08-02-2001	Engle, et al.	
2001/0039392	11-08-2001	Strahilevitz	
2002/0019603	02-14-2002	Strahilevitz	
2002/0058031	05-16-2002	Tung, et al.	
2002/0086276	07-04-2002	Srivastava	
2002/0107469	08-08-2002	Bolan, et al.	
2002/0111577	08-15-2002	Sirimanne, et al.	
2002/0119147	08-29-2002	Howell, et al.	
2002/0159995	10-31-2002	Brady, et al.	
2002/0183677	12-05-2002	Chang, et al.	
2002/0187069	12-12-2002	Levin, et al.	
2002/0197249	12-26-2002	Brady, et al.	
2002/0197250	12-26-2002	Brady, et al.	
2002/0197251	12-26-2002	Brady, et al.	
2003/0073822	04-17-2003	Lofling, et al.	
2003/0118584	06-26-2003	Glenn, et al.	
2003/0125657	07-03-2003	Koll, et al.	
2003/0127390	07-10-2003	Davis, Jr.	
2003/0133929	07-17-2003	Cham	
2003/0138349	07-24-2003	Robinson, et al.	
2003/0148404	08-07-2003	Michaelson	
2003/0163077	08-28-2003	Kim, et al.	
2003/0195452	10-16-2003	Hunley, et al.	
2003/0215443	11-20-2003	Coffey, et al.	
2004/0044301	03-04-2004	Levin, et al.	
2004/0054315	03-18-2004	Levin, et al.	

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,116,589	09-26-1978	Rishton	
4,189,470	02-19-1980	Rose	
4,191,182	03-04-1980	Popovich, et al.	
4,350,156	09-21-1982	Malchesky, et al.	
4,362,155	12-07-1982	Skurkovich	604/6.04
4,375,414	03-01-1983	Strahilevitz	
4,581,010	04-08-1986	Skurkovich, et al.	
4,605,394	08-12-1986	Skurkovich	
4,620,977	11-04-1986	Strahilevitz	

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

4,633,417	12-30-1986	Wilburn, et al.
4,634,417	01-06-1987	Korec
4,664,913	05-12-1987	Mielke, et al.
4,801,449	01-31-1989	Balint, Jr., et al.
4,813,924	03-21-1989	Strahilevitz
4,824,432	04-25-1989	Skurkovich, et al.
4,834,973	05-30-1989	Strahilevitz
4,865,841	09-12-1989	Balint, Jr., et al.
4,963,265	10-16-1990	Okarma, et al.
5,037,645	08-06-1991	Strahilevitz
5,037,649	08-06-1991	Balint, Jr., et al.
5,078,673	01-07-1992	Abrams
5,356,374	10-18-1994	Hogan, et al.
5,605,690	02-25-1997	Jacobs, et al.
5,626,843	05-06-1997	Skurkovich, et al.
5,643,732	07-01-1997	Strahilevitz
5,705,615	01-06-1998	Lini, et al.
5,730,713	03-24-1998	Okarma, et al.
5,753,227	05-19-1998	Strahilevitz
5,840,588	11-24-1998	Strahilevitz
5,869,047	02-09-1999	Blake
5,888,511	03-30-1999	Skurkovich, et al.
5,910,252	06-08-1999	Truitt, et al.
6,039,946	03-21-2000	Strahilevitz
6,197,289	03-06-2001	Wirt, et al.
6,221,614	04-24-2001	Prusiner, et al.
6,245,038	06-12-2001	Borberg, et al.
6,264,623	01-24-2001	Strahilevitz
6,287,516	09-11-2001	Matson, et al.
6,428,790	08-06-2002	Boyd
6,432,405	08-13-2002	Weinberg, et al.
6,528,057	03-04-2003	Ambrus, et al.
6,561,997	05-13-2003	Weitzel, et al.
6,569,112	05-27-2003	Strahilevitz
6,602,502	08-05-2003	Strahilevitz
6,602,993	08-05-2003	Wallach, et al.
6,607,501	08-19-2003	Gorsuch
6,607,723	08-19-2003	Good, et al.
6,627,151	09-30-2003	Borberg, et al.
6,630,315	10-07-2003	Miwa, et al.
6,676,622	01-13-2004	Strahilevitz
6,685,664	02-03-2004	Levin, et al.

U.S.S.N.: 09/709,045
 Filed: November 10, 2000
 SUPPLEMENTAL INFORMATION
 DISCLOSURE STATEMENT

RE 31,688	09-25-1984	Popovich, et al.
RE 36,755	06-27-2000	Smith, et al.

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
3302384	01-25-1983	Lysaght, et al.	DE
0076665	01-14-1987	E.I. Du Pont De Nemours and Company	EP
2136314	09-19-1984	Gelman Sciences, Inc.	GB
56092824	07-27-1981	Terumo Corporation	JP
WO 79/01121	12-27-1979	The Government of the United States of America	PCT

Publications

ABRUZZESE, et al., "A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: Results of a trial terminated by excessive toxicity" *Journal of Biological Response Modifiers* 9:522-527 (1990).

ADOLF AND APFLER, "A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60kDa TNF receptor, in biological fluids" *J. Immunol. Meth.* 143:127-136 (1991).

AJANI, et al., "Phase I and II studies of the combination of recombinant human interferon- γ and 5-fluorouracil in patients with advanced colorectal carcinoma" *Journal of Biological Response Modifiers* 8:140-146 (1989).

ALBERTINI, et al., "Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy" *Journal of Biological Response Modifiers* 9:456-462 (1990).

ARENDS, "Inhibiting the effects of cytokines in human diseases" *Adv. Int. Med.* 40:365-394 (1995).

AVNER, et al., "Therapeutic murine monoclonal antibodies developed for individual cancer patients" *Journal of Biological Response Modifiers* 8:25-36 (1989).

BALCEWICZ-SABLINSKA, et al., "Pathogenic *Mycobacterium tuberculosis* evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF- α " *J. Immunol.* 161:2636-2641 (1998).

U.S.S.N.: 09/709,045

Filed: November 10, 2000

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

BALIKO, et al., "Th2 biased immune response in cases with active *Mycobacterium tuberculosis* infection and tuberculin anergy" *FEMS Immunol. Med. Micro.* 22:188-204 (1998).

BERNUDEZ AND CHAMPSI, "Infection with *Mycobacterium avium* induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice" *Infect. Immun.* 61:3093-3097 (1993).

BEUTLER AND CERAMI, "The biology of cachectin/TNF-A primary mediator of the host response" *Ann. Rev. Immunol.* 7:625-655 (1989).

BLAUER, et al., "Modulation of the antilisterial activity of human blood-derived macrophages by activating and deactivating cytokines" *J. Interferon Cytokine Res.* 15:105-114 (1995).

BOMAN, et al., "Phase I study of recombinant gamma-interferon (rIFN- γ)" *Journal of Biological Response Modifiers* 7:438-446 (1988).

BRUNTSCH, et al., "phase II study of recombinant human interferon- γ in metastatic renal cell carcinoma" *Journal of Biological Response Modifiers* 9:335-338 (1990).

BUKOWSKI, et al., "Phase I trial of continuous infusion of recombinant interleukin-2 and intermittent recombinant interferon- α_2a . Clinical effects" *Journal of Biological Response Modifiers* 9:538-545 (1990).

CAULFIELD, et al., "Phase II-1b trial of an anti- $C_{\beta}3$ monoclonal antibody in combination with interferon- α in patients with malignant melanoma" *Journal of Biological Response Modifiers* 9:319-328 (1990).

CHAMBRIER, et al., "Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients" *Journal of Biological Response Modifiers* 9:251-255 (1990).

CHOUAIB, et al., "More insights into the complex physiology of TNF" *Immunol. Today* 12(5):141-145 (1991).

COCLET-NININ, et al., "Interferon-beta not only inhibits interleukin-1 β and tumor necrosis factor- α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells" *Eur. Cytokine Network* 8(4):345-349 (1997).

COLMAN, et al., Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd. Edition (Colman, et al., eds.) pp. 63-67 J.B. Lippincott: Philadelphia, PA, 1987.

COX, et al., "Phase II study of human lymphoblastoid interferon in patients with multiple myeloma" *Journal of Biological Response Modifiers* 7:318-325 (1988).

U.S.S.N.: 09/709,045

Filed: November 10, 2000

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

CREAVEN, et al., "Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer" *Journal of Biological Response Modifiers* 9:492-498 (1990).

CROGHAN, et al., "A phase I trial of recombinant interferon- α and α -difluoromethylornithine in metastatic melanoma" *Journal of Biological Response Modifiers* 7:409-415 (1988).

D'ANDREA, et al., "Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells" *J. Exp. Med.* 178:1041-1048 (1993).

DIMERY, et al., "Recombinant interferon- γ in the treatment of recurrent nasopharyngeal carcinoma" *Journal of Biological Response Modifiers* 8:221-226 (1989).

DINARELLO, "Induction of interleukin-I and interleukin-I receptor antagonist" *Sem. In Oncol.* 24(no. 3, Suppl. 9):81-93 (1997).

DUPERE, et al., "Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation *in vitro*" *Journal of Biological Response Modifiers* 9:140-148 (1990).

ENGELHARDT, et al., "Biological response to intravenously administered endotoxin in patients with advanced cancer" *Journal of Biological Response Modifiers* 9:480-491 (1990)

ENGELMANN, et al., "Two tumor necrosis factor-binding proteins purified from human urine" *J. Biol. Chem.* 265(3):1531-1536 (1990).

ERIKS AND EMERSON, "Temporal effect of tumor necrosis factor alpha on murine macrophages infected with *Mycobacterium avium*" *Infect. Immun.* 65(6):2100-2106 (1997).

ETGES AND MULLER, "Progressive disease or protective immunity to *Leishmania* major infection: the result of a network of stimulatory and inhibitory interactions" *J. Mol. Med.* 76:372-390 (1998).

FAREED, et al., "Novel antigenic markers of human tumor regression" *Journal of Biological Response Modifiers* 7:11-23 (1988).

FAVROT, et al., "Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma" *Journal of Biological Response Modifiers* 9:167-177 (1990).

FERNANDES AND BALDWIN, "Interleukin-10 downregulates protective immunity to *Brucella abortus*" *Infect. Immun.* 63:1130-1133 (1995).

U.S.S.N.: 09/709,045

Filed: November 10, 2000

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

FOON, et al., "A prospective randomized trial of α_2B -interferon/ γ -interferon or the combination in advanced metastatic renal cell carcinoma" *Journal of Biological Response Modifiers* 7:540-545 (1988).

FROST, et al., "Interleukin-6 induction by a muramyltripeptide derivative in cancer patients" *Journal of Biological Response Modifiers* 9:160-166 (1990).

GADDUCCI, et al., "Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer" *Anticancer Res.* 16:3125-3128 (1996)

GILL, et al., "Interferon-alpha maintenance therapy after cytotoxic chemotherapy for treatment of acquired immunodeficiency syndrome-related kaposi's sarcoma" *Journal of Biological Response Modifiers* 9:512-516 (1990).

GREENBLATT, et al., "The type B receptor for tumor necrosis factor-alpha" *Blood* 80:1339-1346 (1992).

GUSTAVSON, et al., "Pharmacokinetics of tecelukin (Recombinant human inteleukin-2) after intravenous or subcutaneous administration to patients with cancer" *Journal of Biological Response Modifiers* 8:440-449 (1989)

HANDZEL, et al., "Immunomodulation of Tcell deficiency in humans by thymic humoral factor: from crude extract to synthetic thymic humoral factor- γ 2" *Journal of Biological Response Modifiers* 9:269-278 (1990).

HANK, et al., "Depressed *in vitro* T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following *in vivo* treatment with interleukin-2" *Journal of Biological Response Modifiers* 9:5-14 (1990).

HERCEND, et al., "Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: A feasibility trial in metastatic renal cell carcinoma" *Journal of Biological Response Modifiers* 9:546-555 (1990).

HERRMANN, et al., "Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: Assessment of two routes of administration" *Journal of Biological Response Modifiers* 9:475-479 (1990).

HERTLER, et al., "A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia" *Journal of Biological Response Modifiers* 7:97-113 (1988).

HIMMLER, et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein" *DNA and Cell Biol.* 9(10):705-715 (1990).

U.S.S.N.: 09/709,045

Filed: November 10, 2000

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

JACOBS, et al., "minimal antigenicity of intron A in human recipients demonstrated by three analytical methods" *Journal of Biological Response Modifiers* 7:447-456 (1988).

JAKOBSEN, et al., "Decreased antitoxic activities among children with clinical episodes of malaria" *Infect. Immun.* 66(4):1654-1659 (1998).

JAKSCHIES, et al., "Emergence and decay of the human Ms homolog in cancer patients during and after interferon- α therapy" *Journal of Biological Response Modifiers* 9:305-312 (1990).

KALMANTI, et al., "Serum levels of tumor necrosis factor soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma" *Int. J. Hematol.* 57:147-152 (1993).

KAUFMANN, et al., "T cells and cytokines in intracellular bacterial infections: experiences with *Mycobacterium bovis* BCG" *Ciba Fdn. Symp.* 195:123-132 (1995).

KELLOKUMPU-LEHTINEN, et al., "Recombinant interferon- α 2a and vinblastine in advanced renal cell cancer: A clinical phase I-II study" *Journal of Biological Response Modifiers* 9:439-444 (1990).

KESSLER, "Adsorptive plasma treatment: Optimization of extracorporeal devices and systems" *Blood Purification* 11:150-157 (1993).

KHAZAEI, et al., "Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans" *Journal of Biological Response Modifiers* 9:178-184 (1990).

KOLITZ, et al., "Phase I trial of recombinant interleukin-2 and cyclophosphamide: Augmentation of cellular immunity and T-cell mitogenic response with long term administration of rIL-2" *Journal of Biological Response Modifiers* 7:457-472 (1988).

KRIGEL, et al., "Treatment of epidemic kaposi's sarcoma with a combination of interferon-alpha 2b and etoposide" *Journal of Biological Response Modifiers* 7:359-364 (1988).

LANTZ, et al., "Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans" *Cytokine* 2(6):402-406 (1990).

LASELO, et al., "Phase I studies of recombinant interferon- γ " *Journal of Biological Response Modifiers* 9:185-193 (1990).

LAUCELLA, et al., "Papel de las citoquinas en la resistencia y patología durante la infección con *Trypanosoma cruzi*" *Revista Argentina de Microbiología*, 28:99-109 (1996).

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

LENTZ, et al., "Apheresis of low molecular weight protein fraction and the onset of labor" *Journal of Clinical Apheresis* 5:62-67 (1990).

LENTZ, "The phylogeny of oncology" *Mol. Biother.* 2:137-144 (1990).

LETTERIO AND ROBERTS, "Regulation of immune responses by TGF β " *Ann. Rev. Immunol.* 16:137-161 (1998).

LITTON, et al., "Biological and clinical effects of the oral immunomodulator 3,6'Bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy" *Journal of Biological Response Modifiers* 9:61-70 (1990).

LUCEY, et al., "Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases" *Clin. Micro. Rev.* 9(4):532-562 (1996).

MAAS, et al., "Interleukin-2 in cancer treatment: disappointing or (still) promising? A review" *Cancer Immunol. Immunother.* 36:141-148 (1993).

MACA, "Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice" *Journal of Biological Response Modifiers* 9:568-580 (1990).

MARSHALL, et al., "Effects of coumarin (12-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies" *Journal of Biological Response Modifiers* 8:62-69 (1989).

MARSHALL, et al., "Treatment of renal cell carcinoma with daily low-dose alpha-interferon" *Journal of Biological Response Modifiers* 8:453-461 (1989).

MILES, et al., "induction of soluble tumour necrosis factor receptors during treatment with interleukin-2" *Brit. J. Cancer* 66:1195-1199 (1992).

MITTELMAN, et al., "Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2" *Journal of Biological Response Modifiers* 8:468-478 (1989).

MUSIANI, et al., "Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma" *Journal of Biological Response Modifiers* 8:571-578 (1989).

NEIDHART, "Phase I study of recombinant methionyl human consensus interferon (r-mIFN- α -Con)" *Journal of Biological Response Modifiers* 7:240-248 (1988).

U.S.S.N.: 09/709,045

Filed: November 10, 2000

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ORATZ, et al. "Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine" *Journal of Biological Response Modifiers* 8:355-358 (1989).

ORATZ, et al., "Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: Results of a phase II trial" *Journal of Biological Response Modifiers* 9:345-354 (1990).

PAIS, et al., "Pharmacokinetics of recombinant interleukin-2 in children with malignancies: A pediatric oncology group study" *Journal of Biological Response Modifiers* 9:517-521 (1990).

PAOLOZZI, et al., "Phase I trial of recombinant interleukin-2 and recombinant β -interferon in refractory neoplastic diseases" *Journal of Biological Response Modifiers* 8:122-139 (1989).

PEREZ, et al., "A phase I trial of recombinant Human gamma interferon (IFN- γ_4A) in patients with advanced malignancy" *Journal of Biological Response Modifiers* 7:309-317 (1988).

QUESADA, et al., "Recombinant interferon alpha and gamma in combination as treatment for tetastatic renal cell carcinoma" *Journal of Biological Response Modifiers* 7:234-239 (1988).

RABINOWITZ, et al., "Hemolytic anemia in a cancer patient treated with recombinant interferon- γ " *Journal of Biological Response Modifiers* 9:256-259 (1990).

REIMANN, et al., "Suppression of the immune response by micro-organisms" *Scand. J. Immunol.* 31:543-546 (1990).

RIFFKIN, et al., "Defense against the immune barrage: helminth survival strategies" *Immunol. Cell Bio* 74:564-574 (1996)

ROMANI, et al., "T helper cell dichotomy to *Candida albicans*: implications for pathology" *Immunol. Res.* 14:148-162 (1995).

ROSENTHAL, et al., "The *in vitro* function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2" *Journal of Biological Response Modifiers* 7:123-139 (1988).

RYBAK, et al., "Interferon therapy of relapsed and refractory hodgkin's disease: Cancer and leukemia group B study 8652" *Journal of Biological Response Modifiers* 9:1-4 (1990).

U.S.S.N.: 09/709,045

Filed: November 10, 2000

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

SARNA, et al., "Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: Clinical results" *Journal of Biological Response Modifiers* 8:16-24 (1989).

SARNA, et al., "A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects" *Journal of Biological Response Modifiers* 9:81-86 (1990).

SARTHOU, et al., "Prognostic value of anti-*Plasmodium falciparum*-specific immunoglobulin G3, cytokines, and their soluble receptors in west African patients with severe malaria" *Infect. Immun.* 65(8):3271-3276 (1997).

SATO, et al., "induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy" *Journal of Biological Response Modifiers* 9:329-334 (1990).

SCHAADT, et al., "Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma" *Journal of Biological Response Modifiers* 9:247-250 (1990).

SCHALL, et al., "molecular cloning and expression of a receptor for human tumor necrosis factor" *Cell* 61:361-370 (1990).

SCHEITHAUER, et al., "Combined α -2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy a induction therapy in multiple myeloma: A prospective randomized trial" *Journal of Biological Response Modifiers* 8:109-115 (1989).

SCHILLER, et al., "A phase I trial of interferon- α -2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin" *Journal of Biological Response Modifiers* 8:252-261 (1989).

SECKINGER, et al., "Purification and biologic characterization of a specific tumor necrosis factor α inhibitor" *J. Biol. Chem.* 264(20):11966-11973 (1989)

SEIGLER, et al., "Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies" *Journal of Biological Response Modifiers* 8:37-52 (1989).

SHAU, et al., "A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes" *Journal of Biological Response Modifiers* 9:71-80 (1990).

SIDHU AND BOLLON, "Tumor necrosis factor activities and cancer therapy – A perspective" *Pharmacol. Ther.* 57:79-128 (1993).

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

SIELING, et al., "Immunosuppressive roles for IL-10 and IL-4 in human infection" *J. Immunol.* 150(12):5501-5510 (1993).

SPRIGGS, "One step ahead of the game: Viral immunomodulatory molecules" *Ann. Rev. Immunol.* 14:101-130 (1996).

STEGER, et al., "Long-term remission in a patient with erythroleukemia following interferon- α treatment" *Journal of Biological Response Modifiers* 8:351-354 (1989).

STEINMETZ, et al., "Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor" *Journal of Biological Response Modifiers* 7:417-423 (1988).

SZNOL, et al., "A phase I study of high-dose interleukin-2 in combination with interferon α_{2b} " *Journal of Biological Response Modifiers* 9:529-537 (1990).

TRIGG, et al., " α -interferon therapy for lymphoproliferative disorders developing in two children following bone marrow transplants" *Journal of Biological Response Modifiers* 8:603-613 (1989).

TRINCHIERI, et al., "Cytokine cross-talk between phagocytic cells and lymphocytes: Relevance for differentiation/Activation of phagocytic cells and regulation of adaptive immunity" *J. Cell. Biochem.* 53:301-308 (1993).

TRUMP et al., "Interferon- α -n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma" *Journal of Biological Response Modifiers* 9:108-111 (1990).

UMIEL, et al., "Recombinant interleukin-2-activated intracavitory lymphocytes: Phenotypic characteristics and effector function" *Journal of Biological Response Modifiers* 8:409-421 (1989).

VON HOFF, et al., "Phase II evaluation of recombinant γ -interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study" *Journal of Biological Response Modifiers* 9:584-587 (1990).

WALSH, et al., "Phase I study of the combination of alpha-2 interferon and cisplatin" *Journal of Biological Response Modifiers* 8:11-15 (1989).

WEIL-HILLMAN, et al., "Transient decrease in IL-2 responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients" *Journal of Biological Response Modifiers* 7:424-437 (1988).

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

WHITEHEAD, et al., "A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: A southwest oncology group study" *Journal of Biological Response Modifiers* 9:588-591 (1990).

YELAVARTHI, et al., "Analysis of p60 and p80 tumor necrosis factor-alpha" *American Journal of Pathology* 143:1131-1141 (1993).

ZAMKOFF, et al., "A Phase I trial of subcutaneously administered recombinant tumor necrosis factor to patients with advanced malignancy" *Journal of Biological Response Modifiers* 8:539-552 (1989).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Tiffany B. Salmon
Reg. No. 55,589

Dated: April 29, 2005

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2153 (Telephone)
(404) 879-2160 (Fax)

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	09/709,045
				Filing Date	November 10, 2000
				First Named Inventor	M. Rigdon Lentz
				Group Art Unit	1647
				Examiner Name	Lorraine Spector
Sheet	1	of	15	Attorney Docket Number	LEN 102

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		4,116,589		Rishton	09-26-1978	
		4,189,470		Rose	02-19-1980	
		4,191,182		Popovich, et al.	03-04-1980	
		4,350,156		Malchesky, et al.	09-21-1982	
		4,362,155		Skurkovich	12-07-1982	
		4,375,414		Strahilevitz	03-01-1983	
		4,581,010		Skurkovich, et al.	04-08-1986	
		4,605,394		Skurkovich	08-12-1986	
		4,620,977		Strahilevitz	11-04-1986	
		4,633,417		Wilburn, et al.	12-30-1986	
		4,634,417		Korec	01-06-1987	
		4,664,913		Mielke, et al.	05-12-1987	
		4,801,449		Balint, Jr., et al.	01-31-1989	
		4,813,924		Strahilevitz	03-21-1989	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		DE	3302384		Lysaght, et al.	01-25-1983		
		EP	0076665		E.I. Du Pont De Nemours	01-14-1987		
		GB	2136314		Gelman Sciences, Inc.	09-19-1984		
		JP	56092824		Terumo Corporation	07-27-1981		
		PCT	WO 79/01121		The Government of the United States of America	12-27-1979		
Examiner's Signature					Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+ ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet

2

of

15

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		4,824,432		Skurkovich, et al.	04-25-1989	
		4,834,973		Strahilevitz	05-30-1989	
		4,865,841		Balint, Jr., et al.	09-12-1989	
		4,963,265		Okarma, et al.	10-16-1990	
		5,037,645		Strahilevitz	08-06-1991	
		5,037,649		Balint, Jr., et al.	08-06-1991	
		5,078,673		Abrams	01-07-1992	
		5,356,374		Hogan, et al.	10-18-1994	
		5,605,690		Jacobs, et al.	02-25-1997	
		5,626,843		Skurkovich, et al.	05-06-1997	
		5,643,732		Strahilevitz	07-01-1997	
		5,705,615		Lim, et al.	01-06-1998	
		5,730,713		Okarma, et al.	03-24-1998	
		5,753,227		Strahilevitz	05-19-1998	
		5,840,588		Strahilevitz	11-24-1998	
		5,869,047		Blake	02-09-1999	
		5,888,511		Skurkovich, et al.	03-30-1999	
		5,910,252		Truitt, et al.	06-08-1999	
		6,039,946		Strahilevitz	03-21-2000	
		6,197,289		Wirt, et al.	03-06-2001	
		6,221,614		Prusiner, et al.	04-24-2001	
		6,245,038		Borberg, et al.	06-12-2001	
		6,264,623		Strahilevitz	07-24-2001	
		6,287,516		Matson, et al.	09-11-2001	
		6,428,790		Boyd	08-06-2002	
		6,432,405		Weinberg, et al.	08-13-2002	
		6,528,057		Ambrus, et al.	03-04-2003	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

15

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,561,997		Weitzel, et al.	05-13-2003	
		6,569,112		Strahilevitz	05-27-2003	
		6,602,502		Strahilevitz	08-05-2003	
		6,602,993		Wallach, et al.	08-05-2003	
		6,607,501		Gorsuch	08-19-2003	
		6,607,723		Good, et al.	08-19-2003	
		6,627,151		Borberg, et al.	09-30-2003	
		6,630,315		Miwa, et al.	10-07-2003	
		6,676,622		Strahilevitz	01-13-2004	
		6,685,664		Levin, et al.	02-03-2004	
		RE 31,688		Popovich, et al.	09-25-1984	
		RE 36,755		Smith, et al.	06-27-2000	
		2001/0010818		Engle, et al.	08-02-2001	
		2001/0039392		Strahilevitz	11-08-2001	
		2002/0019603		Strahilevitz	02-14-2002	
		2002/0058031		Tung, et al.	05-16-2002	
		2002/0086276		Srivastava	07-04-2002	
		2002/0107469		Bolan, et al.	08-08-2002	
		2002/0111577		Sirimanne, et al.	08-15-2002	
		2002/0119147		Howell, et al.	08-29-2002	
		2002/0159995		Brady, et al.	10-31-2002	
		2002/0183677		Chang, et al.	12-05-2002	
		2002/0187069		Levin, et al.	12-12-2002	
		2002/0197249		Brady, et al.	12-26-2002	
		2002/0197250		Brady, et al.	12-26-2002	
		2002/0197251		Brady, et al.	12-26-2002	
		2003/0073822		Lofling, et al.	04-17-2003	
		2003/0118584		Glenn, et al.	06-26-2003	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+ ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box —



PTO/SB/08A (10-98)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/709,045
		Filing Date	November 10, 2000
		First Named Inventor	M. Riddon Lentz
		Group Art Unit	1647
		Examiner Name	Lorraine Spector
		Attorney Docket Number	LEN 102
Sheet	4	of	15



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 15

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is available.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

Please type a plus sign (+) inside this box →

09709045 - GAU: 1647

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO


Complete if Known

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

Sheet 5 of 15

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ABRUZZESE, et al., "A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: Results of a trial terminated by excessive toxicity" <i>Journal of Biological Response Modifiers</i> 9:522-527 (1990).	
		ADOLF AND APFLER, "A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60kDa TNF receptor, in biological fluids" <i>J. Immunol. Meth.</i> 143:127-136 (1991).	
		AJANI, et al., "Phase I and II studies of the combination of recombinant human interferon-γ and 5-fluorouracil in patients with advanced colorectal carcinoma" <i>Journal of Biological Response Modifiers</i> 8:140-146 (1989).	
		ALBERTINI, et al., "Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy" <i>Journal of Biological Response Modifiers</i> 9:456-462 (1990).	
		ARENDE, "Inhibiting the effects of cytokines in human diseases" <i>Adv. Int. Med.</i> 40:365-394 (1995).	
		AVNER, et al., "Therapeutic murine monoclonal antibodies developed for individual cancer patients" <i>Journal of Biological Response Modifiers</i> 8:25-36 (1989).	
		BALCEWICZ-SABLINSKA, et al., "Pathogenic <i>Mycobacterium tuberculosis</i> evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-α" <i>J. Immunol.</i> 161:2636-2641 (1998).	
		BALIKO, et al., "Th2 biased immune response in cases with active <i>Mycobacterium tuberculosis</i> infection and tuberculin anergy" <i>FEMS Immunol. Med. Micro.</i> 22:188-204 (1998).	
		BERMUDEZ AND CHAMPSI, "Infection with <i>Mycobacterium avium</i> induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice" <i>Infect. Immun.</i> 61:3093-3097 (1993).	
		BEUTLER AND CERAMI, "The biology of cachectin/TNF-A primary mediator of the host response" <i>Ann. Rev. Immunol.</i> 7:625-655 (1989).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet 6 of 15

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lenz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BLAUER, et al., "Modulation of the antileukemic activity of human blood-derived macrophages by activating and deactivating cytokines" <i>J. Interferon Cytokine Res.</i> 15:105-114 (1995).	
		BOMAN, et al., "Phase I study of recombinant gamma-interferon (rIFN-γ)" <i>Journal of Biological Response Modifiers</i> 7:438-446 (1988).	
		BRUNTSCH, et al., "phase II study of recombinant human interferon- γ in metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:335-338 (1990).	
		BUKOWSKI, et al., "Phase I trial of continuous infusion of recombinant interleukin-2 and intermittent recombinant interferon-α _{2a} . Clinical effects" <i>Journal of Biological Response Modifiers</i> 9:538-545 (1990).	
		CAULFIELD, et al., "Phase I1-Ib trial of an anti-G _{D3} monoclonal antibody in combination with interferon-α in patients with malignant melanoma" <i>Journal of Biological Response Modifiers</i> 9:319-328 (1990).	
		CHAMBRIER, et al., "Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients" <i>Journal of Biological Response Modifiers</i> 9:251-255 (1990).	
		CHOUAIB, et al., "More insights into the complex physiology of TNF" <i>Immunol. Today</i> 12(5):141-145 (1991).	
		COCLET-NININ, et al., "Interferon-beta not only inhibits interleukin-1β and tumor necrosis factor-α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells" <i>Eur. Cytokine Network</i> 8(4):345-349 (1997).	
		COLMAN, et al., <i>Hemostasis and Thrombosis: Basic Principles and Clinical Practice</i> 2nd. Edition (Colman, et al., eds.) pp. 63-67 J.B. Lippincott: Philadelphia, PA, 1987.	
		COX, et al., "Phase II study of human lymphoblastoid interferon in patients with multiple myeloma" <i>Journal of Biological Response Modifiers</i> 7:318-325 (1988).	
		CREAVEN, et al., "Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer" <i>Journal of Biological Response Modifiers</i> 9:492-498 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 15

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CROGHAN, et al., "A phase I trial of recombinant interferon- α and α -difluoromethylornithine in metastatic melanoma" <i>Journal of Biological Response Modifiers</i> 7:409-415 (1988).	
		D'ANDREA, et al., "Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells" <i>J. Exp. Med.</i> 178:1041-1048 (1993).	
		DIMERY, et al., "Recombinant interferon- γ in the treatment of recurrent nasopharyngeal carcinoma" <i>Journal of Biological Response Modifiers</i> 8:221-226 (1989).	
		DINARELLO, "Induction of interleukin-I and interleukin-I receptor antagonist" <i>Sem. In Oncol.</i> 24(no. 3, Suppl. 9):81-93 (1997).	
		DUPERE, et al., "Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation <i>in vitro</i> " <i>Journal of Biological Response Modifiers</i> 9:140-148 (1990).	
		ENGELHARDT, et al., "Biological response to intravenously administered endotoxin in patients with advanced cancer" <i>Journal of Biological Response Modifiers</i> 9:480-491 (1990)	
		ENGELMANN, et al., "Two tumor necrosis factor-binding proteins purified from human urine" <i>J. Biol. Chem.</i> 265(3):1531-1536 (1990).	
		ERIKS AND EMERSON, "Temporal effect of tumor necrosis factor alpha on murine macrophages infected with <i>Mycobacterium avium</i> " <i>Infect. Immun.</i> 65(6):2100-2106 (1997).	
		ETGES AND MULLER, "Progressive disease or protective immunity to <i>Leishmania major</i> infection: the result of a network of stimulatory and inhibitory interactions" <i>J. Mol. Med.</i> 76:372-390 (1998).	
		FAREED, et al., "Novel antigenic markers of human tumor regression" <i>Journal of Biological Response Modifiers</i> 7:11-23 (1988).	
		FAVROT, et al., "Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:167-177 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+ ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 15

Complete if Known

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FERNANDES AND BALDWIN, "Interleukin-10 downregulates protective immunity to <i>Brucella abortus</i> " <i>Infect. Immun.</i> 63:1130-1133 (1995).	
		FOON, et al., "A prospective randomized trial of α_{2B} -interferon/ γ -interferon or the combination in advanced metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 7:540-545 (1988).	
		FROST, et al., "Interleukin-6 induction by a muramyltripeptide derivative in cancer patients" <i>Journal of Biological Response Modifiers</i> 9:160-166 (1990).	
		GADDUCCI, et al., "Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer" <i>Anticancer Res.</i> 16:3125-3128 (1996).	
		GILL, et al., "Interferon-alpha maintenance therapy after cytotoxic chemotherapy for treatment of acquired immunodeficiency syndrome-related kaposi's sarcoma" <i>Journal of Biological Response Modifiers</i> 9:512-516 (1990).	
		GREENBLATT, et al., "The type B receptor for tumor necrosis factor-alpha" <i>Blood</i> 80:1339-1346 (1992).	
		GUSTAVSON, et al., "Pharmacokinetics of teceleukin (Recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer" <i>Journal of Biological Response Modifiers</i> 8:440-449 (1989).	
		HANDZEL, et al., "Immunomodulation of T cell deficiency in humans by thymic humoral factor: from crude extract to synthetic thymic humoral factor- γ 2" <i>Journal of Biological Response Modifiers</i> 9:269-278 (1990).	
		HANK, et al., "Depressed <i>in vitro</i> T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following <i>in vivo</i> treatment with interleukin-2" <i>Journal of Biological Response Modifiers</i> 9:5-14 (1990).	
		HERCEND, et al., "Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: A feasibility trial in metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:546-555 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+ ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box → Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

Sheet 9 of 15

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HERRMANN, et al., "Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: Assessment of two routes of administration" <i>Journal of Biological Response Modifiers</i> 9:475-479 (1990).	
		HERTLER, et al., "A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia" <i>Journal of Biological Response Modifiers</i> 7:97-113 (1988).	
		HIMMLER, et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein" <i>DNA and Cell Biol.</i> 9(10):705-715 (1990).	
		JACOBS, et al., "minimal antigenicity of intron A in human recipients demonstrated by three analytical methods" <i>Journal of Biological Response Modifiers</i> 7:447-456 (1988).	
		JAKOBSEN, et al., "Decreased antitoxic activities among children with clinical episodes of malaria" <i>Infect. Immun.</i> 66(4):1654-1659 (1998).	
		JAKSCHIES, et al., "Emergence and decay of the human Ms homolog in cancer patients during and after interferon- α therapy" <i>Journal of Biological Response Modifiers</i> 9:305-312 (1990).	
		KALMANTI, et al., "Serum levels of tumor necrosis factor soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma" <i>Int. J. Hematol.</i> 57:147-152 (1993).	
		KAUFMANN, et al., "T cells and cytokines in intracellular bacterial infections: experiences with <i>Mycobacterium bovis BCG</i> " <i>Ciba Fdn. Symp.</i> 195:123-132 (1995).	
		KELLOKUMPU-LEHTINEN, et al., "Recombinant interferon- α 2a and vinblastine in advanced renal cell cancer: A clinical phase I-II study" <i>Journal of Biological Response Modifiers</i> 9:439-444 (1990).	
		KESSLER, "Adsorptive plasma treatment: Optimization of extracorporeal devices and systems" <i>Blood Purification</i> 11:150-157 (1993).	
		KHAZAEILI, et al., "Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans" <i>Journal of Biological Response Modifiers</i> 9:178-184 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet 10 of 15

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lenz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		KOLITZ, et al., "Phase I trial of recombinant interleukin-2 and cyclophosphamide: Augmentation of cellular immunity and T-cell mitogenic response with long term administration of rIL-2" <i>Journal of Biological Response Modifiers</i> 7:457-472 (1988).	
		KRIGEL, et al., "Treatment of epidemic kaposi's sarcoma with a combination of interferon-alpha 2b and etoposide" <i>Journal of Biological Response Modifiers</i> 7:359-364 (1988).	
		LANTZ, et al., "Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans" <i>Cytokine</i> 2(6):402-406 (1990).	
		LASZLO, et al., "Phase I studies of recombinant interferon-γ" <i>Journal of Biological Response Modifiers</i> 9:185-193 (1990).	
		LAUCELLA, et al., "Papel de las citoquinas en la resistencia y patología durante la infección con <i>Trypanosoma cruzi</i> " <i>Revista Argentina de Microbiología</i> , 28:99-109 (1996).	
		LENTZ, et al., "Apheresis of low molecular weight protein fraction and the onset of labor" <i>Journal of Clinical Apheresis</i> 5:62-67 (1990).	
		LENTZ, "The phylogeny of oncology" <i>Mol. Biother.</i> 2:137-144 (1990).	
		LETTERIO AND ROBERTS, "Regulation of immune responses by TGF-β" <i>Ann. Rev. Immuno.</i> 16:137-161 (1998).	
		LITTON, et al., "Biological and clinical effects of the oral immunomodulator 3,6'Bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy" <i>Journal of Biological Response Modifiers</i> 9:61-70 (1990).	
		LUCEY, et al., "Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases" <i>Clin. Micro. Rev.</i> 9(4):532-562 (1996).	
		MAAS, et al., "Interleukin-2 in cancer treatment: disappointing or (still) promising? A review" <i>Cancer Immunol. Immunother.</i> 36:141-148 (1993).	
<hr/>			
<hr/>			
Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	11	of	15	Attorney Docket Number	LEN 102
-------	----	----	----	------------------------	---------

Complete if Known

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MACA, "Inhibition of the growth of lewis lung carcinoma by indomethacin in conventional , nude, and beige mice" <i>Journal of Biological Response Modifiers</i> 9:568-580 (1990).	
		MARSHALL, et al., "Effects of coumarin (12-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies" <i>Journal of Biological Response Modifiers</i> 8:62-69 (1989).	
		MARSHALL, et al., "Treatment of renal cell carcinoma with daily low-dose alpha-interferon" <i>Journal of Biological Response Modifiers</i> 8:453-461 (1989).	
		MILES, et al., "induction of soluble tumour necrosis factor receptors during treatment with interleukn-2" <i>Brit. J. Cancer</i> 66:1195-1199 (1992).	
		MITTELMAN, et al., "Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activatiated killer (LAK) cell infusions and recombinant human interleukin-2" <i>Journal of Biological Response Modifiers</i> 8:468-478 (1989).	
		MUSIANI, et al., "Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma" <i>Journal of Biological Response Modifiers</i> 8:571-578 (1989).	
		NEIDHART, "Phase I study of recombinant methionyl human consensus interferon (r-metHuIFN-Con)" <i>Journal of Biological Response Modifiers</i> 7:240-248 (1988).	
		ORATZ, et al. "Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine" <i>Journal of Biological Response Modifiers</i> 8:355-358 (1989).	
		ORATZ, et al., "Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: Results of a phase II trial" <i>Journal of Biological Response Modifiers</i> 9:345-354 (1990).	
		PAIS, et al., "Pharmacokinetics of recombinant interleukin-2 in children with malignancies: A pediatric oncology group study" <i>Journal of Biological Response Modifiers</i> 9:517-521 (1990).	
Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+ ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 15

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		PAOLOZZI, et al., "Phase I trial of recombinant interleukin-2 and recombinant β -interferon in refractory neoplastic diseases" <i>Journal of Biological Response Modifiers</i> 8:122-139 (1989).	
		PEREZ, et al., "A phase I trial of recombinant human gamma interferon (IFN- γ 4A) in patients with advanced malignancy" <i>Journal of Biological Response Modifiers</i> 7:309-317 (1988).	
		QUESADA, et al., "Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 7:234-239 (1988).	
		RABINOWITZ, et al., "Hemolytic anemia in a cancer patient treated with recombinant interferon- γ " <i>Journal of Biological Response Modifiers</i> 9:256-259 (1990).	
		REIMANN, et al., "Suppression of the immune response by micro-organisms" <i>Scand. J. Immunol.</i> 31:543-546 (1990).	
		RIFFKIN, et al., "Defense against the immune barrage: helminth survival strategies" <i>Immunol. Cell Bio</i> 74:564-574 (1996)	
		ROMANI, et al., "T helper cell dichotomy to <i>Candida albicans</i> : implications for pathology" <i>Immunol. Res.</i> 14:148-162 (1995).	
		ROSENTHAL, et al., "The <i>in vitro</i> function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2" <i>Journal of Biological Response Modifiers</i> 7:123-139 (1988).	
		RYBAK, et al., "Interferon therapy of relapsed and refractory hodgkin's disease: Cancer and leukemia group B study 8652" <i>Journal of Biological Response Modifiers</i> 9:1-4 (1990).	
		SARNA, et al., "Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: Clinical results" <i>Journal of Biological Response Modifiers</i> 8:16-24 (1989).	
		SARNA, et al., "A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects" <i>Journal of Biological Response Modifiers</i> 9:81-86 (1990).	
		SARTHOU, et al., "Prognostic value of anti- <i>Plasmodium falciparum</i> -specific immunoglobulin G3, cytokines, and their soluble receptors in west African patients with severe malaria" <i>Infect. Immun.</i> 65(8):3271-3276 (1997).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+ ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

Please type a plus sign (+) inside this box →



09709045 - GAU: 1647

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number 09/709,045 Filing Date November 10, 2000 First Named Inventor M. Rigdon Lentz Group Art Unit 1647 Examiner Name Lorraine Spector Attorney Docket Number LEN 102	
Sheet	13	of	15

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SATO, et al., "induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy" <i>Journal of Biological Response Modifiers</i> 9:329-334 (1990).	
		SCHAADT, et al., "Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma" <i>Journal of Biological Response Modifiers</i> 9:247-250 (1990).	
		SCHALL, et al., "molecular cloning and expression of a receptor for human tumor necrosis factor" <i>Cell</i> 61:361-370 (1990).	
		SCHEITHAUER, et al., "Combined α -2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy a induction therapy in multiple myeloma: A prospective randomized trial" <i>Journal of Biological Response Modifiers</i> 8:109-115 (1989).	
		SCHILLER, et al., "A phase I trial of interferon- α -2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin" <i>Journal of Biological Response Modifiers</i> 8:252-261 (1989).	
		SECKINGER, et al., "Purification and biologic characterization of a specific tumor necrosis factor α inhibitor" <i>J. Biol. Chem.</i> 264(20):11966-11973 (1989).	
		SEIGLER, et al, "Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies" <i>Journal of Biological Response Modifiers</i> 8:37-52 (1989).	
		SHAU, et al., "A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes" <i>Journal of Biological Response Modifiers</i> 9:71-80 (1990).	
		SIDHU AND BOLLON, "Tumor necrosis factor activities and cancer therapy – A perspective" <i>Pharmacol. Ther.</i> 57:79-128 (1993).	
		SIELING, et al., "Immunosuppressive roles for IL-10 and IL-4 in human infection" <i>J. Immunol.</i> 150(12):5501-5510 (1993).	
		SPRIGGS, "One step ahead of the game: Viral immunomodulatory molecules" <i>Ann. Rev. Immunol.</i> 14:101-130 (1996).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

09709045 - GAU: 1647

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 15

Complete if Known

Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	LEN 102

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		STEGER, et al., "Long-term remission in a patient with erythroleukemia following interferon- α treatment" <i>Journal of Biological Response Modifiers</i> 8:351-354 (1989).	
		STEINMETZ, et al., "Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor" <i>Journal of Biological Response Modifiers</i> 7:417-423 (1988).	
		SZNOL, et al., "A phase I study of high-dose interleukin-2 in combination with interferon α_{2b} " <i>Journal of Biological Response Modifiers</i> 9:529-537 (1990).	
		TRIGG, et al., " α -interferon therapy for lymphoproliferative disorders developing in two children following bone marrow transplants" <i>Journal of Biological Response Modifiers</i> 8:603-613 (1989).	
		TRINCHIERI, et al., "Cytokine cross-talk between phagocytic cells and lymphocytes: Relevance for differentiation/Activation of phagocytic cells and regulation of adaptive immunity" <i>J. Cell. Biochem.</i> 53:301-308 (1993).	
		TRUMP et al., "Interferon- α -n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:108-111 (1990).	
		UMIEL, et al., "Recombinant interleukin-2-activated intracavitary lymphocytes: Phenotypic characteristics and effector function" <i>Journal of Biological Response Modifiers</i> 8:409-421 (1989).	
		VON HOFF, et al., "Phase II evaluation of recombinant γ -interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study" <i>Journal of Biological Response Modifiers</i> 9:584-587 (1990).	
		WALSH, et al., "Phase I study of the combination of alpha-2 interferon and cisplatin" <i>Journal of Biological Response Modifiers</i> 8:11-15 (1989).	
		WEIL-HILLMAN, et al., "Transient decrease in IL-2 responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients" <i>Journal of Biological Response Modifiers</i> 7:424-437 (1988).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 05/04/2005

Please type a plus sign (+) inside this box →

+

09709045 - GAU: 1647

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>		Application Number	09/709,045
		Filing Date	November 10, 2000
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	1647
		Examiner Name	Lorraine Spector
		Attorney Docket Number	LEN 102
Sheet	15	of	15



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 15

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Signature	/Cherie M. Woodward/	Date Considered	11/08/2011
----------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/